Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Change in Account Payables (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Change in Account Payables for 13 consecutive years, with $355000.0 as the latest value for Q4 2025.

  • Quarterly Change in Account Payables fell 54.95% to $355000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $326000.0 through Dec 2025, down 56.53% year-over-year, with the annual reading at $326000.0 for FY2025, 56.53% down from the prior year.
  • Change in Account Payables for Q4 2025 was $355000.0 at Theravance Biopharma, down from $538000.0 in the prior quarter.
  • The five-year high for Change in Account Payables was $5.1 million in Q2 2021, with the low at -$5.7 million in Q4 2021.
  • Average Change in Account Payables over 5 years is -$203200.0, with a median of $82000.0 recorded in 2024.
  • Peak annual rise in Change in Account Payables hit 344.55% in 2025, while the deepest fall reached 36550.0% in 2025.
  • Over 5 years, Change in Account Payables stood at -$5.7 million in 2021, then surged by 34.46% to -$3.8 million in 2022, then skyrocketed by 90.75% to -$348000.0 in 2023, then surged by 326.44% to $788000.0 in 2024, then plummeted by 54.95% to $355000.0 in 2025.
  • According to Business Quant data, Change in Account Payables over the past three periods came in at $355000.0, $538000.0, and -$733000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.